ResMed Inc. logo

ResMed Inc. (RMD)

Market Open
5 Dec, 20:33
NYSE NYSE
$
256. 83
+5.32
+2.12%
$
37.49B Market Cap
27.49 P/E Ratio
1.92% Div Yield
37,498 Volume
6.52 Eps
$ 251.51
Previous Close
Day Range
254.4 257.98
Year Range
199.92 293.81
Want to track RMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 48 days
Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 8 months ago
Is it Worth Adding ResMed Stock to Your Portfolio Now?

Is it Worth Adding ResMed Stock to Your Portfolio Now?

Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.

Zacks | 9 months ago
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?

ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

Zacks | 9 months ago
Here's Why ResMed (RMD) is a Strong Growth Stock

Here's Why ResMed (RMD) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 9 months ago
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)

3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)

ResMed (RMD) could produce exceptional returns because of its solid growth attributes.

Zacks | 9 months ago
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher

Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher

ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks | 9 months ago
Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 9 months ago
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished.

Seekingalpha | 9 months ago
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 10 months ago
Stock Of The Day: Trading The Range In ResMed

Stock Of The Day: Trading The Range In ResMed

ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.

Benzinga | 10 months ago
Here's Why ResMed (RMD) is a Strong Momentum Stock

Here's Why ResMed (RMD) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 10 months ago
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 10 months ago
Loading...
Load More